

Robert B Raffa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3092666/publications.pdf>

Version: 2024-02-01

225
papers

8,494
citations

50276

46
h-index

58581

82
g-index

230
all docs

230
docs citations

230
times ranked

7577
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential neurological manifestations of COVID-19: a narrative review. <i>Postgraduate Medicine</i> , 2022, 134, 395-405.	2.0	22
2	The epidemiology of apnoea of prematurity. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 685-693.	1.5	5
3	Treating Apnea of Prematurity. <i>Cureus</i> , 2022, 14, e21783.	0.5	4
4	Kratom use in the United States: a diverse and complex profile. <i>Addiction</i> , 2021, 116, 202-203.	3.3	14
5	The Zika virus: Lurking behind the COVID-19 pandemic?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 267-276.	1.5	17
6	Bone fractures during the time of coronavirus. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 543-546.	1.5	9
7	The Challenge of Polysubstance Use Overdose. <i>Open Journal of Social Sciences</i> , 2021, 09, 529-542.	0.3	1
8	Neuronal Effects of Listening to Entrainment Music Versus Preferred Music in Patients With Chronic Cancer Pain as Measured via EEG and LORETA Imaging. <i>Frontiers in Psychology</i> , 2021, 12, 588788.	2.1	8
9	The problem of postoperative respiratory depression. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1220-1225.	1.5	1
10	Are opioid receptor antagonists adequate for "Opioid" overdose in a changing reality?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 861-866.	1.5	2
11	Benefit-Risk Analysis of Buprenorphine for Pain Management. <i>Journal of Pain Research</i> , 2021, Volume 14, 1359-1369.	2.0	16
12	Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1501-1504.	1.5	13
13	Wooden Chest syndrome: The atypical pharmacology of fentanyl overdose. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1505-1508.	1.5	14
14	Pharmacologic agents directed at the treatment of pain associated with maladaptive neuronal plasticity. <i>Expert Opinion on Pharmacotherapy</i> , 2021, , 1-12.	1.8	6
15	The conundrum of polysubstance overdose. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1189-1193.	1.5	4
16	Benzodiazepines: Thinking outside the black box. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 554-559.	1.5	9
17	The limited management options for apnoea of prematurity. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, , .	1.5	0
18	Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. <i>Pain Medicine</i> , 2020, 21, 714-723.	1.9	57

#	ARTICLE	IF	CITATIONS
19	Developments in combined analgesic regimens for improved safety in postoperative pain management. Expert Review of Neurotherapeutics, 2020, 20, 981-990.	2.8	2
20	Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 892-903.	1.5	104
21	Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache. Drugs of Today, 2020, 56, 5.	1.1	6
22	<p>The Polysubstance Overdose-Death Crisis</p>. Journal of Pain Research, 2020, Volume 13, 3405-3408.	2.0	33
23	Commentary: New Complications Make Treatment of ‘Opioid’ Overdose Challenging. Pharmacology & Pharmacy, 2020, 11, 362-372.	0.7	0
24	Discovery of ‘folded DNA’ structures in human cells: Potential drug targets. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 125-128.	1.5	2
25	‘Cigarettes for smoking cessation: Do they deliver?’. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 650-655.	1.5	8
26	Treating opioid-induced constipation in patients taking other medications: Avoiding CYP450 drug interactions. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 361-371.	1.5	6
27	Treating pain in patients with dementia and the possible concomitant relief of symptoms of agitation. Pain Management, 2019, 9, 569-582.	1.5	6
28	<p>Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain</p>. Journal of Pain Research, 2019, Volume 12, 3299-3317.	2.0	27
29	Sunscreen bans: Coral reefs and skin cancer. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 134-139.	1.5	65
30	Knowledge, Attitude and Practice Survey of Prescribing Opioids for Chronic Noncancer Pain in Taiwan’ Comparison of Pain and Non-Pain Physicians. Pain Medicine, 2019, 20, 2397-2410.	1.9	10
31	<i>Commentary</i>: Benzodiazepine (BZD) and Related BZD-Receptor Agonists: Basic Science Reasons to Limit to Four Weeks or Less. Pharmacology & Pharmacy, 2019, 10, 357-364.	0.7	2
32	Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain. Pain and Therapy, 2018, 7, 37-57.	3.2	14
33	Abuse-deterrent opioids: an update on current approaches and considerations. Current Medical Research and Opinion, 2018, 34, 711-723.	1.9	28
34	Indirect-acting strategy of opioid action instead of direct receptor activation: dual-acting enkephalinase inhibitors (DENKIs). Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 443-449.	1.5	10
35	Curcumin in turmeric: Basic and clinical evidence for a potential role in analgesia. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 460-466.	1.5	39
36	Nature's first ‘atypical opioids’ Kratom and mitragynines. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 437-441.	1.5	27

#	ARTICLE	IF	CITATIONS
37	The role and mechanism of action of menthol in topical analgesic products. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 313-319.	1.5	55
38	The fentanyl family: A distinguished medical history tainted by abuse. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 154-158.	1.5	30
39	The rapid-onset antidepressant effect of ketamine: More surprises?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 308-311.	1.5	3
40	Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin. <i>Postgraduate Medicine</i> , 2018, 130, 1-8.	2.0	81
41	Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. <i>Clinical Drug Investigation</i> , 2018, 38, 259-268.	2.2	30
42	Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin κ and classical opioid receptors in the rat spinal nerve ligation model. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00444.	2.4	12
43	Designing safer analgesics: a focus on μ -opioid receptor pathways. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 965-972.	5.0	29
44	Does "Strong Analgesic" Equal "Strong Opioid"? Tapentadol and the Concept of "µ-Load". <i>Advances in Therapy</i> , 2018, 35, 1471-1484.	2.9	50
45	What's holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholders. <i>Expert Opinion on Drug Delivery</i> , 2018, 15, 567-576.	5.0	2
46	Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product. <i>Journal of Pain Research</i> , 2018, Volume 11, 301-311.	2.0	11
47	Driving under the influence of opioids: What prescribers should know. <i>Journal of Opioid Management</i> , 2018, 14, 415-427.	0.5	7
48	A Guide for Cancer Pain Management in Latin America. <i>Journal of Cancer Research Updates</i> , 2018, 6, 81-96.	0.3	0
49	What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 147-154.	1.5	63
50	Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 467-477.	2.3	23
51	Considering tapentadol as a first-line analgesic: 14 questions. <i>Pain Management</i> , 2017, 7, 331-339.	1.5	8
52	The effects of food on opioid-induced nausea and vomiting and pharmacological parameters: a systematic review. <i>Postgraduate Medicine</i> , 2017, 129, 698-708.	2.0	1
53	The Basic Pharmacology of Opioids Informs the Opioid Discourse about Misuse and Abuse: A Review. <i>Pain and Therapy</i> , 2017, 6, 1-16.	3.2	36
54	Long-term use of opioids in 210 officially registered patients with chronic noncancer pain in Taiwan: A cross-sectional study. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 257-265.	1.7	16

#	ARTICLE	IF	CITATIONS
55	Safety of buprenorphine transdermal system in the management of pain in older adults. <i>Postgraduate Medicine</i> , 2017, 129, 92-101.	2.0	13
56	The "Darknet": The new street for street drugs. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 790-792.	1.5	20
57	Application of human factors engineering (HFE) to the design of a naloxone auto-injector for the treatment of opioid emergencies. <i>Drug Delivery and Translational Research</i> , 2017, 7, 1-10.	5.8	16
58	Cebranopadol: novel dual opioid/NOP receptor agonist analgesic. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 8-17.	1.5	34
59	Peripherally acting μ -opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 107-119.	1.8	29
60	Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system. <i>Journal of Pain Research</i> , 2017, Volume 10, 1255-1263.	2.0	10
61	Management of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technology. <i>Journal of Pain Research</i> , 2016, Volume 9, 909-916.	2.0	11
62	Comments and Suggestions from Pain Specialists Regarding the <sc>CDC</sc>'s Proposed Opioid Guidelines. <i>Pain Practice</i> , 2016, 16, 794-808.	1.9	7
63	Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials. <i>Pain Practice</i> , 2016, 16, 345-358.	1.9	19
64	The Centers for Disease Control and Prevention opioid guidelines: potential for unintended consequences and will they be abused?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 592-593.	1.5	9
65	Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 371-382.	1.5	88
66	Change Pain: Ever Evolving? An Update for 2016. <i>Pain and Therapy</i> , 2016, 5, 127-133.	3.2	12
67	Perspectives on Intravenous Oxycodone for Control of Postoperative Pain. <i>Pain Practice</i> , 2016, 16, 924-934.	1.9	19
68	Evolution to low-dose NSAID therapy. <i>Pain Management</i> , 2016, 6, 175-189.	1.5	8
69	Good clinical practice guide for opioids in pain management: the three Ts " titration (trial), tweaking (tailoring), transition (tapering). <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2016, 66, 310-317.	0.4	9
70	A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression. <i>Pain Practice</i> , 2016, 16, 473-485.	1.9	6
71	A Guide for Pain Management in Developing Nations: The Diagnosis and Assessment of Pain in Cancer Patients. <i>Journal of Cancer Research Updates</i> , 2016, 5, 29-44.	0.3	0
72	Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 615-619.	1.5	9

#	ARTICLE	IF	CITATIONS
73	The role of abuse-deterrent formulations in countering opioid misuse and abuse. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 629-634.	1.5	6
74	Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. <i>Journal of Pain Research</i> , 2015, 8, 229.	2.0	22
75	The unsolved case of “bone-impairing analgesics”; the endocrine effects of opioids on bone metabolism. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 515.	2.0	56
76	<i>Clostridium difficile</i> infection: A brief update on emerging therapies. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 1007-1012.	1.0	20
77	Is levorphanol a better option than methadone?. <i>Pain Medicine</i> , 2015, 16, 1673-1679.	1.9	24
78	Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 125-130.	1.5	25
79	Stereochemistry and neuropharmacology of a α -bath salt TM cathinone: S-enantiomer of mephedrone reduces cocaine-induced reward and withdrawal in invertebrates. <i>Neuropharmacology</i> , 2015, 91, 109-116.	4.1	22
80	Maximizing value in opioid utilization: Is oxycodone immediate release a good option for pain management?. <i>Agri Dergisi</i> , 2015, 27, 1-11.	0.2	0
81	Combining Opioid and Adrenergic Mechanisms for Chronic Pain. <i>Postgraduate Medicine</i> , 2014, 126, 98-114.	2.0	16
82	α -Selective TM COX-1 or COX-2 NSAIDs: time to change a misleading measure. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 455-456.	1.5	4
83	Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 25-37.	1.5	58
84	A modern analgesics pain α -pyramid TM . <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 4-6.	1.5	43
85	Opioid formulations with sequestered naltrexone: a perspective review. <i>Therapeutic Advances in Drug Safety</i> , 2014, 5, 129-137.	2.4	2
86	Sequestered naltrexone in sustained release morphine or oxycodone α a way to inhibit illicit use?. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 181-190.	2.4	8
87	Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness. <i>Sleep Disorders</i> , 2014, 2014, 1-9.	1.4	4
88	The clinical analgesic efficacy of buprenorphine. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 577-583.	1.5	74
89	Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit. <i>European Journal of Pain</i> , 2014, 18, 1148-1156.	2.8	13
90	On subclasses of opioid analgesics. <i>Current Medical Research and Opinion</i> , 2014, 30, 2579-2584.	1.9	16

#	ARTICLE	IF	CITATIONS
91	Acetaminophen (Paracetamol) Oral Absorption and Clinical Influences. <i>Pain Practice</i> , 2014, 14, 668-677.	1.9	51
92	Treating Acute Pain in Light of the Chronification of Pain. <i>Pain Management Nursing</i> , 2014, 15, 380-390.	0.9	39
93	Levamisole and cocaine synergism: A prevalent adulterant enhances cocaine's action in vivo. <i>Neuropharmacology</i> , 2014, 79, 590-595.	4.1	52
94	Short Overview of Mitragynines. , 2014, , 9-22.		0
95	A Review of Duloxetine 60mg Once-Daily Dosing for the Management of Diabetic Peripheral Neuropathic Pain, Fibromyalgia, and Chronic Musculoskeletal Pain Due to Chronic Osteoarthritis Pain and Low Back Pain. <i>Pain Practice</i> , 2013, 13, 239-252.	1.9	72
96	The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 350-359.	1.5	26
97	Cocaine synergism with alpha agonists in rat aorta: Computational analysis reveals an action beyond reuptake inhibition. <i>Drug and Alcohol Dependence</i> , 2013, 129, 226-231.	3.2	6
98	Opioid receptor types involved in the development of nicotine physical dependence in an invertebrate (Planaria) model. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 112, 9-14.	2.9	8
99	Cancer survivor-care™: II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive) Tj ETQq1 1 0.7843 14 rgB9 /Overlo		
100	Sucrose produces withdrawal and dopamine-sensitive reinforcing effects in planarians. <i>Physiology and Behavior</i> , 2013, 112-113, 8-13.	2.1	19
101	Tapentadol Extended Release for Chronic Pain Patients. <i>Advances in Therapy</i> , 2013, 30, 14-27.	2.9	17
102	Opioid antagonists for pain. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 517-525.	4.1	12
103	Orally Active Opioid Compounds from a Non-Poppy Source. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4840-4848.	6.4	34
104	Vitamin D and type 2 diabetes mellitus. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 81-84.	1.5	9
105	Opioid-Induced Hyperalgesia: Is It Clinically Relevant for the Treatment of Pain Patients?. <i>Pain Management Nursing</i> , 2013, 14, e67-e83.	0.9	34
106	Tramadol/Paracetamol Fixed-Dose Combination for Chronic Pain Management in Family Practice: A Clinical Review. <i>ISRN Family Medicine</i> , 2013, 2013, 1-15.	0.4	8
107	Designing Opioids That Deter Abuse. <i>Pain Research and Treatment</i> , 2012, 2012, 1-10.	1.7	35
108	Mechanistic and functional differentiation of tapentadol and tramadol. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1437-1449.	1.8	125

#	ARTICLE	IF	CITATIONS
109	Mephedrone (â€œbath saltâ€) pharmacology: insights from invertebrates. <i>Neuroscience</i> , 2012, 208, 79-84.	2.3	39
110	Fixed-dose combinations for emerging treatment of pain. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1261-1270.	1.8	20
111	QTc interval prolongation by <i>d</i> -propoxyphene: what about other analgesics?. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1397-1409.	1.8	20
112	Pain Treatment in Arthritis-Related Pain: Beyond NSAIDs. <i>Open Rheumatology Journal</i> , 2012, 6, 320-330.	0.2	104
113	Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain. <i>Journal of Pain Research</i> , 2012, 5, 327.	2.0	32
114	The evolving understanding of the analgesic mechanism of action of flupirtine. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 4-6.	1.5	22
115	Multi-mechanistic analgesia for opioid-induced hyperalgesia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 125-127.	1.5	14
116	CB1-independent mechanisms of δ^9 -THCV, AM251 and SR141716 (rimonabant). <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 260-265.	1.5	16
117	Continuous Multimechanistic Postoperative Analgesia: A Rationale for Transitioning from Intravenous Acetaminophen and Opioids to Oral Formulations. <i>Pain Practice</i> , 2012, 12, 159-173.	1.9	26
118	A Randomized, Double-blind Comparison Shows the Addition of Oxygenated Glycerol Triesters to Topical Mentholated Cream for the Treatment of Acute Musculoskeletal Pain Demonstrates Incremental Benefit Over Time. <i>Pain Practice</i> , 2012, 12, 610-619.	1.9	8
119	Intracerebroventricular opioids for intractable pain. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 34-41.	2.4	23
120	â€Null Methodâ™ Determination of Drug Biophase Concentration. <i>Pharmaceutical Research</i> , 2012, 29, 637-642.	3.5	1
121	Extended-release formulations of tramadol in the treatment of chronic pain. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1757-1768.	1.8	23
122	007. A randomized, double-blind comparison of the addition of oxygenated glycerol triesters to topical mentholated cream for the treatment of acute musculoskeletal pain. <i>European Journal of Pain Supplements</i> , 2011, 5, 509-510.	0.0	0
123	008. Preliminary observations of a novel topical oil with analgesic properties for treatment of acute and chronic pain syndromes. <i>European Journal of Pain Supplements</i> , 2011, 5, 510-510.	0.0	0
124	009. Safe use of fluoroquinolones: A focus on limiting CNS and peripheral neuropathy adverse events. <i>European Journal of Pain Supplements</i> , 2011, 5, 510-510.	0.0	0
125	Nicotine behavioral pharmacology: Clues from planarians. <i>Drug and Alcohol Dependence</i> , 2011, 118, 274-279.	3.2	51
126	Naltrexone extended-release injection: an option for the management of opioid abuse. <i>Substance Abuse and Rehabilitation</i> , 2011, 2, 219.	4.8	3

#	ARTICLE	IF	CITATIONS
127	On the criteria for classifying opiate agonists in rats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 34, 525-526.	2.4	12
128	Tolerance and cross-tolerance studies with morphine and ethylketocyclazocine. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 34, 666-667.	2.4	25
129	A proposed mechanism for chemotherapy-related cognitive impairment (â€˜chemo-fogâ€™). <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 257-259.	1.5	36
130	Deciphering the mechanism(s) of action of natural products: analgesic peroxide oil as example. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 283-298.	1.5	5
131	Cancer â€˜survivor-careâ€™: I. the $\alpha 7$ nAChR as potential target for chemotherapy-related cognitive impairment. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 437-445.	1.5	7
132	Glutamate and aspartate measurements in individual planaria by rapid capillary electrophoresis. <i>Journal of Pharmacological and Toxicological Methods</i> , 2011, 63, 119-122.	0.7	26
133	Potential insight for drug discovery from high-fidelity receptor-mediated transduction mechanisms in insects. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 1091-1101.	5.0	0
134	Effects of repeated administration of chemotherapeutic agents tamoxifen, methotrexate, and 5-fluorouracil on the acquisition and retention of a learned response in mice. <i>Psychopharmacology</i> , 2011, 217, 539-548.	3.1	41
135	Adolescent drug use: altered dopamine feedback control. <i>FASEB Journal</i> , 2011, 25, 1083.8.	0.5	0
136	First evidence that drugs of abuse produce behavioral sensitization and cross sensitization in planarians. <i>Behavioural Pharmacology</i> , 2010, 21, 301-313.	1.7	27
137	The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations. , 2010, 127, 165-174.		47
138	Topiramate-antagonism of L-glutamate-induced paroxysms in planarians. <i>European Journal of Pharmacology</i> , 2010, 649, 150-153.	3.5	23
139	Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile. <i>Pain Practice</i> , 2010, 10, 428-450.	1.9	244
140	Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in â€˜chemo-fogâ€™/â€˜chemo-brainâ€™. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 1-9.	1.5	26
141	Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced â€˜chemo-fogâ€™. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 249-255.	1.5	21
142	What do we (not) know about how paracetamol (acetaminophen) works?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 617-638.	1.5	99
143	Imaging as a Means of Studying Chemotherapy-Related Cognitive Impairment. <i>Advances in Experimental Medicine and Biology</i> , 2010, 678, 70-76.	1.6	5
144	Opioid Formulations Designed to Resist/Deter Abuse. <i>Drugs</i> , 2010, 70, 1657-1675.	10.9	85

#	ARTICLE	IF	CITATIONS
145	European perspectives on upcoming analgesics: What do they have that we don'tâ€”and what do they think about them?. <i>Techniques in Regional Anesthesia and Pain Management</i> , 2010, 14, 86-98.	0.2	0
146	5-HT1A-like receptor activation inhibits abstinence-induced methamphetamine withdrawal in planarians. <i>Neuroscience Letters</i> , 2010, 484, 113-117.	2.1	8
147	Diselenium, instead of disulfide, bonded analogs of conotoxins: novel synthesis and pharmacotherapeutic potential. <i>Life Sciences</i> , 2010, 87, 451-456.	4.3	11
148	On deriving the doseâ€”effect relation of an unknown second component: An example using buprenorphine preclinical data. <i>Drug and Alcohol Dependence</i> , 2010, 109, 126-129.	3.2	10
149	The Determination and Application of Fixed-Dose Analgesic Combinations for Treating Multimodal Pain. <i>Journal of Pain</i> , 2010, 11, 701-709.	1.4	76
150	Short Introduction and History. <i>Advances in Experimental Medicine and Biology</i> , 2010, 678, 1-10.	1.6	3
151	Chemotherapy-Related Visual System Toxicity. <i>Advances in Experimental Medicine and Biology</i> , 2010, 678, 113-118.	1.6	3
152	Oxycodone combinations for pain relief. <i>Drugs of Today</i> , 2010, 46, 379.	1.1	24
153	Future Directions. <i>Advances in Experimental Medicine and Biology</i> , 2010, 678, 165-167.	1.6	0
154	Chemo fog: cancer chemotherapy-related cognitive impairment. Preface. <i>Advances in Experimental Medicine and Biology</i> , 2010, 678, vii-viii.	1.6	5
155	Patient's perspective. <i>Advances in Experimental Medicine and Biology</i> , 2010, 678, 11-2.	1.6	0
156	Considerations on the use of oxymorphone in geriatric patients. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 603-613.	2.4	14
157	Topiramate antagonizes NMDA- and AMPA-induced seizure-like activity in planarians. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 93, 363-367.	2.9	50
158	The M ₅ muscarinic receptor as possible target for treatment of drug abuse. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2009, 34, 623-629.	1.5	26
159	Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. <i>British Journal of Pharmacology</i> , 2009, 157, 831-843.	5.4	38
160	Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. <i>Psychopharmacology</i> , 2008, 199, 527-538.	3.1	65
161	Agmatine: Identification and inhibition of methamphetamine, kappa opioid, and cannabinoid withdrawal in planarians. <i>Synapse</i> , 2008, 62, 927-934.	1.2	17
162	Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine,) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 5	1.9	710

#	ARTICLE	IF	CITATIONS
163	Basic pharmacology relevant to drug abuse assessment: tramadol as example. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 33, 101-108.	1.5	82
164	The μ -opioid receptor antagonist nor-BNI inhibits cocaine and amphetamine, but not cannabinoid (WIN) Tj ETQq0 0 0 rgBT /Overlock 10 <i>Brain Research</i> , 2008, 1193, 51-56.	2.2	15
165	The β -lactam antibiotic ceftriaxone inhibits physical dependence and abstinence-induced withdrawal from cocaine, amphetamine, methamphetamine, and clorazepate in planarians. <i>European Journal of Pharmacology</i> , 2008, 584, 278-284.	3.5	29
166	Nociceptin attenuates methamphetamine abstinence-induced withdrawal-like behavior in planarians. <i>Neuropeptides</i> , 2008, 42, 229-237.	2.2	10
167	Withdrawal-like behavior in planarians is dependent on drug exposure duration. <i>Neuroscience Letters</i> , 2008, 439, 84-88.	2.1	22
168	Unexceptional Seizure Potential of Tramadol or Its Enantiomers or Metabolites in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 325, 500-506.	2.5	47
169	PTX-insensitive Gz transduction pathway contributes to buprenorphine-induced supraspinal, but not spinal, antinociception. <i>FASEB Journal</i> , 2008, 22, 1125.10.	0.5	0
170	Acquisition, retention, or spontaneous recovery learning is impaired in mice by weekly treatments of 5-fluorouracil or methotrexate. <i>FASEB Journal</i> , 2008, 22, 614-614.	0.5	1
171	Looking beyond the administered drug: metabolites of opioid analgesics. <i>Journal of Family Practice</i> , 2008, 57, S25-32.	0.2	2
172	Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonist. <i>Acute Pain</i> , 2007, 9, 145-152.	0.1	37
173	The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB ₁ receptor antagonism ? or inverse agonism ? as potential obesity treatment and other therapeutic use. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007, 32, 209-231.	1.5	79
174	Nonlinear isobologram and superadditive withdrawal from cocaine:cannabinoid combinations in planarians. <i>European Journal of Pharmacology</i> , 2007, 556, 89-90.	3.5	10
175	Flumazenil-sensitive dose-related physical dependence in planarians produced by two benzodiazepine and one non-benzodiazepine benzodiazepine-receptor agonists. <i>European Journal of Pharmacology</i> , 2007, 564, 88-93.	3.5	14
176	An NMDA antagonist (LY 235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 52212-2). <i>Pharmacology Biochemistry and Behavior</i> , 2007, 86, 499-504.	2.9	33
177	Effects of chemotherapeutic agents on learning and memory in mice. <i>FASEB Journal</i> , 2007, 21, .	0.5	0
178	Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006, 31, 129-138.	1.5	64
179	Pharmacological aspects of successful long-term analgesia. <i>Clinical Rheumatology</i> , 2006, 25, 9-15.	2.2	44
180	Schild (apparent pA2) analysis of a μ -opioid antagonist in Planaria. <i>European Journal of Pharmacology</i> , 2006, 540, 200-201.	3.5	6

#	ARTICLE	IF	CITATIONS
181	Modified "Joyce model"™ of opioid dependence/withdrawal. <i>European Journal of Pharmacology</i> , 2006, 551, 54-57.	3.5	1
182	A nitric oxide synthase inhibitor (L-NAME) attenuates abstinence-induced withdrawal from both cocaine and a cannabinoid agonist (WIN 55212-2) in Planaria. <i>Brain Research</i> , 2006, 1099, 82-87.	2.2	25
183	Subadditive withdrawal from cocaine/ μ -opioid agonist combinations in Planaria. <i>Brain Research</i> , 2006, 1114, 31-35.	2.2	15
184	Measurement of glutamate and aspartate in Planaria. <i>Journal of Pharmacological and Toxicological Methods</i> , 2006, 53, 291-295.	0.7	34
185	Amphetamine-induced increase in planarian locomotor activity and block by UV light. <i>Brain Research</i> , 2005, 1031, 138-140.	2.2	24
186	Description and quantification of cocaine withdrawal signs in Planaria. <i>Brain Research</i> , 2005, 1032, 200-202.	2.2	39
187	A reverse-phase HPLC and fluorescence detection method for measurement of 5-hydroxytryptamine (serotonin) in Planaria. <i>Journal of Pharmacological and Toxicological Methods</i> , 2005, 51, 73-76.	0.7	38
188	Bacterial Communication ("Quorum Sensing") via Ligands and Receptors: A Novel Pharmacologic Target for the Design of Antibiotic Drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 417-423.	2.5	110
189	Protonation effect on drug affinity. <i>European Journal of Pharmacology</i> , 2004, 483, 323-324.	3.5	7
190	Opioid receptors and acetaminophen (paracetamol). <i>European Journal of Pharmacology</i> , 2004, 503, 209-210.	3.5	35
191	Cocaine and μ -opioid withdrawal in Planaria blocked by d-, but not l-, glucose. <i>Brain Research</i> , 2004, 1018, 181-185.	2.2	19
192	Isothermal Titration Calorimetric Study of RNase-A Kinetics (cCMP \hat{A} 3'-CMP) Involving End-Product Inhibition. <i>Pharmaceutical Research</i> , 2004, 21, 1642-1647.	3.5	11
193	Mechanism of action of analgesics used to treat osteoarthritis pain. <i>Rheumatic Disease Clinics of North America</i> , 2003, 29, 733-745.	1.9	6
194	μ -Opioid withdrawal in Planaria. <i>Neuroscience Letters</i> , 2003, 349, 139-142.	2.1	31
195	Combination strategies for pain management. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1697-1708.	1.8	60
196	Antinociceptive Synergy, Additivity, and Subadditivity with Combinations of Oral Glucosamine Plus Nonopioid Analgesics in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 307, 699-704.	2.5	37
197	Disruption of a drug-induced choice behavior by UV light. <i>Behavioural Pharmacology</i> , 2003, 14, 569-571.	1.7	14
198	Critical Evaluation of Reported Plant Sources of Possibly Novel Analgesic Compounds. <i>Reviews in Analgesia</i> , 2003, 7, 97-117.	0.9	1

#	ARTICLE	IF	CITATIONS
199	Toward the Design of Ribonuclease (RNase) Inhibitors: Ion Effects on the Thermodynamics of Binding of 2'-5'-Bisphosphate (2'-5'-Bp) to RNase A. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 301, 925-929.	2.5	7
200	Toward RNase inhibitors: thermodynamics of 2'-5'-Bp/RNase-A binding in multi-ion buffer. <i>Biochemical Pharmacology</i> , 2002, 63, 1937-1939.	4.4	5
201	Differential tramadol and O-desmethyl metabolite levels in brain vs. plasma of mice and rats administered tramadol hydrochloride orally. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2002, 27, 99-106.	1.5	32
202	Potential novel targets for Alzheimer pharmacotherapy: I. Secretases. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2002, 27, 169-183.	1.5	24
203	Antihistamines as analgesics. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001, 26, 81-85.	1.5	50
204	Pharmacology of oral combination analgesics: rational therapy for pain. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001, 26, 257-264.	1.5	230
205	Unexpected and pronounced antinociceptive synergy between spinal acetaminophen (paracetamol) and phentolamine. <i>European Journal of Pharmacology</i> , 2001, 412, R1-R2.	3.5	20
206	Cocaine withdrawal in Planaria. <i>European Journal of Pharmacology</i> , 2001, 430, 143-145.	3.5	65
207	Quantitative assessment of dopamine D2 antagonist activity using invertebrate (Planaria) locomotion as a functional endpoint. <i>Journal of Pharmacological and Toxicological Methods</i> , 2001, 45, 223-226.	0.7	78
208	Could a common biochemical mechanism underlie addictions?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 25, 11-20.	1.5	35
209	Energy-dependent UV light-induced disruption of (α)sulpiride antagonism of dopamine. <i>European Journal of Pharmacology</i> , 2000, 406, R11-R12.	3.5	26
210	Discovery of "self-synergistic" spinal/supraspinal antinociception produced by acetaminophen (paracetamol). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2000, 295, 291-4.	2.5	54
211	Loss of antiallodynic and antinociceptive spinal/supraspinal morphine synergy in nerve-injured rats: restoration by MK-801 or dynorphin antiserum. <i>Brain Research</i> , 1999, 831, 55-63.	2.2	81
212	Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats. <i>Pain</i> , 1999, 82, 65-72.	4.2	105
213	Response surface analysis of synergism between morphine and clonidine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1999, 289, 8-13.	2.5	57
214	Orphanin-FQ/nociceptin: Lack of antinociceptive, hyperalgesic or allodynic effects in acute thermal or mechanical tests following intracerebroventricular or intrathecal administration to mice or rats. <i>European Journal of Pain</i> , 1998, 2, 267-278.	2.8	25
215	EFFICIENT DESIGNS FOR STUDYING SYNERGISTIC DRUG COMBINATIONS. <i>Life Sciences</i> , 1997, 61, PL417-PL425.	4.3	113
216	Lack of binding of acetaminophen to 5-HT receptor or uptake sites (or eleven other binding/uptake) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	4.3	39

#	ARTICLE	IF	CITATIONS
217	Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. <i>European Journal of Pharmacology</i> , 1996, 316, 369-372.	3.5	70
218	The α -glibenclamide-shift TM of centrally-acting antinociceptive agents in mice. <i>Brain Research</i> , 1995, 677, 277-282.	2.2	50
219	Testing for synergism over a range of fixed ratio drug combinations: Replacing the isobologram. <i>Life Sciences</i> , 1995, 58, PL23-PL28.	4.3	69
220	Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1995, 274, 1263-70.	2.5	231
221	Topiramate: Preclinical Evaluation of a Structurally Novel Anticonvulsant. <i>Epilepsia</i> , 1994, 35, 450-460.	5.1	326
222	G-protein antisense oligodeoxyribonucleotides and μ -opioid supraspinal antinociception. <i>European Journal of Pharmacology</i> , 1994, 258, R5-R7.	3.5	77
223	Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1993, 267, 331-40.	2.5	301
224	Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1992, 260, 275-85.	2.5	746
225	Ultraviolet light-induced photorelaxation of agonist-contracted rabbit aorta: Further characterization and the estimation of drug-receptor rate constants. <i>Drug Development Research</i> , 1985, 5, 359-369.	2.9	8